(Q44153213)

English

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer

scientific article published on 17 July 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

quality of life

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Sandra M. Swain

9

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

2

object named as

J Baselga

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

author name string

Y-H Im

3

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

S-A Im

4

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

X Pivot

5

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

G Ross

6

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

E Clark

7

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

A Knott

8

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

publication date

17 July 2013

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

2630-2635

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Oncologists' use of quality of life information: results of a survey of Eastern Cooperative Oncology Group physicians.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Exploration of oncologists' attitudes toward and perceived value of patient-reported outcomes

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Health-related quality-of-life measurement in randomized clinical trials in breast cancer--taking stock

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Quality-of-life measurement in randomized clinical trials in breast cancer: an updated systematic review (2001-2009).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Retrospective study of the effect of disease progression on patient reported outcomes in HER-2 negative metastatic breast cancer patients

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193).

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Effect of trastuzumab on health-related quality of life in patients with HER2-positive metastatic breast cancer: data from three clinical trials

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Quality-of-life and quality-adjusted survival (Q-TWiST) in patients receiving lapatinib in combination with paclitaxel as first-line treatment for metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDT274

21 January 2018

Identifiers

10.1093/ANNONC/MDT274

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44153213&oldid=2107209103"